Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term outcomes after aflibercept treatment for retinopathy of prematurity (Study 20090 extension)
2018-003180-54Phase 3Active
- Sponsor
- Bayer
- Start
- Apr 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aflibercept in retinopathy of prematurity (ROP), sponsored by Bayer. Primary endpoint: Binocular best-corrected visual acuity at 5 years. Started Apr 2019; status: active.
02
Drugs
aflibercept
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2018-003180-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003180-54.